We develop a portfolio of long-acting injection products in various therapeutic areas by combining our BEPO® proprietary technology with existing and already-marketed active pharmaceutical ingredients.
Our most advanced products, which address the treatment of schizophrenia and postoperative orthopedic pain, are respectively in a Phase III and Phase II clinical trial in the United States.
The analysts listed above follow Medincell. Any opinions, estimates or forecasts regarding Medincell’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions ofMedincell or its management. Medincell does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Requests for copies of analyst reports should be directly addressed to the above-mentioned analyst and institution.
Nom de la news / 03/04/18
+33 (0)6 83 25 21 86
Louis-Victor Delouvrier /
+33 (0)1 44 71 94 94